Dec 17 2012
ProMining Therapeutics, Ltd. today announced a new collaboration with Roche (SIX: RO, ROG; OTCQX: RHHBY) in the field of type 2 diabetes mellitus. Under the terms of the agreement, ProMining Therapeutics will use its CavitIIRx platform to develop small molecule therapeutics for treatment of type 2 diabetes mellitus and will receive research based funding. Further details of the agreement were not disclosed.
"We are pleased to have completed this agreement with Roche and are very excited by the prospect of jointly delivering novel therapeutic oral small molecules to patients suffering from type 2 diabetes mellitus. ProMining has developed novel technology for the discovery of small molecules interfering in protein-protein interactions that are clearly differentiated from conventional small molecule drugs. This partnership will enable ProMining to expand the exploitation of this technology by combining with the impressive global research and development capabilities and resources of Roche," says Dr. Iris Alroy , ProMining Therapeutics CEO.
SOURCE ProMining Therapeutics Ltd
Healthy eating, physical activity, and medication: Type 2 diabetes patients' willingness to engage varies